{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:15:02Z","timestamp":1792800902691,"version":"4.5.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Tocilizumab (TCZ) is an interleukin-6 receptor inhibitor used in the treatment of rheumatoid arthritis and other inflammatory disorders. Oral ulcerative events have been described as an infrequently reported and potentially underrecognized effect of TCZ, but their clinical characteristics, frequency, and relationship to treatment remain incompletely characterized. This study aimed to map and characterize the available clinical evidence on oral ulcerative events reported during TCZ treatment and to present a clinical case.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>A scoping review was conducted and reported in accordance with PRISMA-ScR guidelines. Peer-reviewed studies reporting oral ulceration, stomatitis, aphthous ulceration, or related oral mucosal events in adults receiving TCZ were included. A clinical case of recurrent oral ulceration temporally associated with TCZ therapy was also described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventeen studies were included, comprising six clinical trials, five observational studies, and six case-report publications. Oral events were variably reported as oral or mouth ulceration, stomatitis, aphthous ulceration, or mucosal ulceration. Detailed information regarding lesion morphology, anatomical distribution, time to onset, duration, and resolution was frequently unavailable, particularly in clinical trials and observational studies. Reported events represented distinct clinical patterns, including newly occurring treatment-emergent events, recurrence following rechallenge, and persistence, lack of therapeutic response, or worsening of pre-existing disease-related ulceration. In the present case, recurrent painful oral ulcerations appeared approximately 24\u2005h after the first TCZ injection and recurred following subsequent doses. Their frequency and severity gradually decreased following multidisciplinary management and subsequent discontinuation of TCZ, with complete resolution reported at the latest follow-up, nine months after TCZ withdrawal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Oral ulcerative events are infrequently reported during TCZ therapy and may be underrecognized; however, the available evidence is heterogeneous and does not establish a uniform clinical phenotype or a definitive causal relationship. Pre-existing disease-related ulceration should be distinguished from newly occurring treatment-emergent events. Careful assessment of temporal relationships, underlying disease, concomitant therapies, and alternative etiologies is important when evaluating oral ulceration in patients receiving TCZ.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1905880","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:07:01Z","timestamp":1789553221000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Tocilizumab-associated oral ulcerations: a case report and scoping review"],"prefix":"10.3389","volume":"13","author":[{"given":"Suad","family":"Aljohani","sequence":"first","affiliation":[{"name":"Department of Oral Diagnostic Sciences, Faculty of Dentistry, King Abdulaziz University","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebtihaj T.","family":"Nafea","sequence":"additional","affiliation":[{"name":"Department of Preventive Dental Sciences, Dental College, Taibah University","place":["Madinah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40259-013-0076-8","article-title":"Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis","volume":"28","author":"Dhillon","year":"2014","journal-title":"BioDrugs"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","article-title":"Tocilizumab: a review in rheumatoid arthritis","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"B3","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/DDDT.S41437","article-title":"Tocilizumab in the treatment of rheumatoid arthritis and beyond","volume":"8","author":"Sweiss","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1002\/art.23940","article-title":"Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B5","doi-asserted-by":"publisher","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.annder.2012.11.006","article-title":"Persistent aphthous mouth ulcers associated with tocilizumab: two cases","volume":"140","author":"Samimi","year":"2013","journal-title":"Ann Dermatol Venereol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.semarthrit.2016.03.016","article-title":"Tocilizumab-induced mucosal ulcers in a patient with relapsing polychondritis: an adverse drug reaction?","volume":"46","author":"Vitiello","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1093\/rheumatology\/kev255","article-title":"Failure of tocilizumab therapy in a patient with mouth and genital ulcers with inflamed cartilage syndrome complicated by aortic aneurysm: table 1","volume":"54","author":"Terreaux","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s10067-014-2589-z","article-title":"Paradoxical mucocutaneous flare in a case of beh\u00e7et\u2019s disease treated with tocilizumab","volume":"34","author":"Cantarini","year":"2015","journal-title":"Clin Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.semarthrit.2020.05.017","article-title":"Effectiveness of tocilizumab in behcet\u2019s disease: a systematic literature review","volume":"50","author":"Akiyama","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"B12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1055\/s-0030-1255931","article-title":"Multiple ulcers in the small and large intestines occurred during tocilizumab therapy for rheumatoid arthritis","volume":"43","author":"Iwasa","year":"2011","journal-title":"Endoscopy"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.2169\/internalmedicine.8031-21","article-title":"A rare case of rheumatoid arthritis with tocilizumab-induced intestinal mucosal injury","volume":"61","author":"Ohkubo","year":"2022","journal-title":"Intern Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e34118","DOI":"10.1097\/MD.0000000000034118","article-title":"Tocilizumab-induced mucosal injury in the terminal ileum mimicking intestinal beh\u00e7et\u2019s disease: a case report","volume":"102","author":"Ozaka","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1748-5908-5-69","article-title":"Scoping studies: advancing the methodology","volume":"5","author":"Levac","year":"2010","journal-title":"Implement Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1136\/ard.2006.068064","article-title":"Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x-ray reader-blinded randomised controlled trial of tocilizumab","volume":"66","author":"Nishimoto","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3109\/s10165-008-0125-1","article-title":"Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy","volume":"19","author":"Nishimoto","year":"2009","journal-title":"Mod Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1111\/cts.13584","article-title":"A phase I study comparing the pharmacokinetics and safety of HS628 (tocilizumab biosimilar) and reference tocilizumab in healthy male subjects","volume":"16","author":"Qian","year":"2023","journal-title":"Clin Transl Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1080\/1744666X.2022.2060204","article-title":"Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trial","volume":"18","author":"Schwabe","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"B22","first-page":"54","article-title":"Effectiveness and tolerability of tocilizumab in patients with rheumatoid arthritis refractory to conventional disease modifying anti rheumatic drugs therapy","volume":"34","author":"Kamal","year":"2020","journal-title":"J Postgrad Med Inst"},{"key":"B23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jbspin.2019.08.002","article-title":"Effectiveness and tolerance of off-label use of tocilizumab in autoimmune diseases: a multicenter study","volume":"87","author":"Michaud","year":"2020","journal-title":"Joint Bone Spine"},{"key":"B24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jbspin.2014.07.010","article-title":"Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis","volume":"82","author":"Pers","year":"2015","journal-title":"Joint Bone Spine"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e16682","DOI":"10.1097\/MD.0000000000016682","article-title":"Refractory adult-onset still disease treated by tocilizumab combined with methotrexate","volume":"98","author":"Wang","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.55563\/clinexprheumatol\/9ipkcs","article-title":"Tocilizumab in beh\u00e7et\u2019s disease with refractory ocular and\/or neurological involvement: response according to different clinical phenotypes","volume":"39","author":"Atienza-Mateo","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/270315","article-title":"Anti-interleukin-6 receptor antibody therapy-induced retinopathy in a patient with rheumatoid arthritis","volume":"2012","author":"Tada","year":"2012","journal-title":"Case Rep Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1093\/rheumatology\/ket130","article-title":"Lack of efficacy of tocilizumab in mucocutaneous beh\u00e7et\u2019s syndrome: report of two cases","volume":"52","author":"Diamantopoulos","year":"2013","journal-title":"Rheumatology (United Kingdom)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3109\/19390211.2013.830679","article-title":"The CARE guidelines: consensus-based clinical case report guideline development","volume":"10","author":"Gagnier","year":"2013","journal-title":"J Diet Suppl"},{"key":"B30","volume-title":"The use of the wHO-UMC System for Standardised Case Causality Assessment","year":"2018"},{"key":"B31","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1093\/rheumatology\/key361","article-title":"Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis","volume":"58","author":"Emery","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/S1470-2045(14)70319-5","article-title":"Siltuximab for multicentric castleman\u2019s disease: a randomised, double-blind, placebo-controlled trial","volume":"15","author":"van Rhee","year":"2014","journal-title":"Lancet Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"Colchicine\u2014update on mechanisms of action and therapeutic uses","volume":"45","author":"Leung","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"B34","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 Update of the EULAR recommendations for the management of beh\u00e7et\u2019s syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1186\/s12903-023-03634-3","article-title":"Correction: topical betamethasone and systemic colchicine for treatment of recurrent aphthous stomatitis: a randomised clinical trial","volume":"23","author":"Alsahaf","year":"2023","journal-title":"BMC Oral Health"},{"key":"B36","doi-asserted-by":"publisher","first-page":"169","DOI":"10.5114\/reum.2021.107026","article-title":"Safety and efficacy of tocilizumab for rheumatoid arthritis: a\u00a0systematic review and metaanalysis of clinical trial studies","volume":"59","author":"Saki","year":"2021","journal-title":"Reumatologia"},{"key":"B37","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/rheumatology\/keq343","article-title":"Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials","volume":"50","author":"Campbell","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/acr2.11226","article-title":"Giant cell arteritis: a systematic review and meta-analysis of test accuracy and benefits and Harms of common treatments","volume":"3","author":"Dua","year":"2021","journal-title":"ACR Open Rheumatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1905880\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:07:02Z","timestamp":1789553222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1905880\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":38,"alternative-id":["10.3389\/fmed.2026.1905880"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1905880","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"1905880"}}